Oxford Biomedica licenses viral vector platforms to Australian CDMO VVMF

The latest update is out from Oxford BioMedica ( (GB:OXB) ).

Oxford Biomedica has signed a five-year licensing and option agreement with Viral Vector Manufacturing Facility, Australia’s first dedicated commercial viral vector CDMO, granting it a worldwide, non-exclusive licence to OXB’s inAAVate platform and an option over its LentiVector technology. In return for an upfront low single‑digit million fee and potential future payments, VVMF will use OXB’s platforms to accelerate its operational readiness and build advanced viral vector manufacturing capabilities, strengthening Australia’s role as an APAC hub and extending OXB’s global reach and reputation as a trusted provider of scalable, high‑quality viral vector solutions.

The most recent analyst rating on (GB:OXB) stock is a Buy with a £950.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Spark’s Take on OXB Stock

According to Spark, TipRanks’ AI Analyst, OXB is a Neutral.

The score is primarily held back by weak financial performance—ongoing losses, negative cash flows, and high leverage—despite strong recent revenue growth. Technicals are supportive due to a strong uptrend and positive MACD, but very overbought RSI/Stoch readings add near-term downside risk. Valuation is constrained by negative earnings and the absence of a dividend yield.

To see Spark’s full report on OXB stock, click here.

More about Oxford BioMedica

Oxford Biomedica (OXB) is a UK-headquartered, quality- and innovation-led contract development and manufacturing organisation specialising in cell and gene therapy. With around 30 years’ experience in viral vectors, it provides end-to-end development and manufacturing services in lentiviral, adeno-associated and other viral vectors to global pharma and biotech clients, supported by advanced platform technologies and facilities in the UK, France and the U.S.

Average Trading Volume: 358,225

Technical Sentiment Signal: Buy

Current Market Cap: £770M

For a thorough assessment of OXB stock, go to TipRanks’ Stock Analysis page.